Neurocrine Biosciences, Inc. (NBIX) Guidance & Earnings Results
On 2026-07-30 Neurocrine Biosciences, Inc. raised guidance: "INGREZZA FY2026 guidance raised to $2.825-$2.875B from…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NBIXNeurocrine Biosciences, Inc.Follow NBIX — free
—
Price chart with a free account
- Market cap
- 14.5B
- P/E TTM
- 20.9
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 30 Jul 26 | Raised | INGREZZA FY2026 guidance raised to $2.825-$2.875B from $2.7-$2.8B · full year |
| 5 May 26 | Reaffirmed | FY2026 INGREZZA net sales guidance $2.7-2.8B · full year |
| 11 Feb 26 | Raised | INGREZZA FY2026 guidance $2.7-2.8B vs FY2025 actual $2.51B · full year |
| 30 Jul 25 | Reaffirmed | INGREZZA 2025 net product sales guidance narrowed to $2.5-2.55B from $2.5-2.6B · full year |
Neurocrine Biosciences, Inc. — questions
- What guidance did Neurocrine Biosciences, Inc. give?
- On 2026-07-30: "INGREZZA FY2026 guidance raised to $2.825-$2.875B from $2.7-$2.8B"
- When does Neurocrine Biosciences, Inc. report earnings?
- Neurocrine Biosciences, Inc.'s next earnings report is expected on 2026-11-02.
Every figure on this page comes from Neurocrine Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.